DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time Boerse Frankfurt Warrants 08:01:13 2024-07-12 am EDT | ||
| 0.61 EUR | +8.93% |
|
| Current month | -12.50% | ||
| 1 month | -11.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.61 | +8.93% |
| 24-07-11 | 0.56 | -8.20% |
| 24-07-10 | 0.61 | +3.39% |
| 24-07-09 | 0.59 | -6.35% |
| 24-07-08 | 0.63 | +1.61% |
Real-time Boerse Frankfurt Warrants
Last update July 12, 2024 at 08:01 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1UNB |
| ISIN | DE000VD1UNB6 |
| Date issued | 2024-03-07 |
| Strike | 160 $ |
| Maturity | 2025-06-20 (343 Days) |
| Parity | 10 : 1 |
| Emission price | 0.37 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.71 € |
|---|---|
| Lowest since issue | 0.38 € |
| Spread | 0.01 € |
| Spread % | 1.61% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Certificates
- Certificat
